Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.51 |
| ▸ | SKP1 | P63208 | 2/20 | 0.51 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 3/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 3/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721746 | 0.87 | KIT (0.43) | KITMAPK1 | |
| SCHEMBL3729051 | 0.82 | JAK1 (0.56) | CKS1BSKP1SKP2KITBACE1 | |
| SCHEMBL3717739 | 0.82 | CKS1B (0.50) | CKS1BSKP1SKP2KITBACE1 | |
| SCHEMBL3717407 | 0.81 | CKS1B (0.53) | CKS1BSKP1SKP2KITBACE1 | |
| SCHEMBL3723265 | 0.80 | AKT1 (0.49) | MAPK1MEN1KMT2A | |
| SCHEMBL3727949 | 0.79 | AKT1 (0.41) | MAPK1 | |
| SCHEMBL3723373 | 0.78 | AKT1 (0.39) | CKS1BSKP1SKP2KITALK | |
| SCHEMBL3723369 | 0.78 | AKT1 (0.51) | KIT | |
| SCHEMBL3723414 | 0.78 | ROCK1 (0.44) | KITMAPK1MEN1TSHRKMT2A | |
| SCHEMBL3718272 | 0.77 | AKT1 (0.50) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841304-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| CN-101959887-B | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC | 2013-07-31 | — | — | CN | disclosed |
| EP-2242755-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-12 | — | — | EP | disclosed |
| CN-101959887-A | Pyrrolopyridine as kinase inhibitor | ARRAY BIOPHARMA INC | 2011-01-26 | — | — | CN | disclosed |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2242755-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009089352-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | CKS1B 24/4885SKP1 63/4885SKP2 18/4885 |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | CKS1B 27/4885SKP1 61/4885SKP2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.